Day: January 18, 2023

NoHo Partners Plc INVESTOR NEWS 18 JANUARY 2023 AT 08:00 EET NoHo Partners selected as the main supplier for restaurant services by Helsinki Expo and Convention Centre The restaurant company NoHo Partners has been selected as the main supplier for restaurant services by Helsinki Expo and Convention Centre (brand name Messukeskus) as of 1 July 2023. Helsinki Expo and Convention Centre is the largest venue for exhibitions, meetings and congresses in Finland, hosting national and international events for about a million visitors annually. The annual revenue from the restaurant services at the convention centre is approximately EUR 15 million. The cooperation with Helsinki Expo and Convention Centre is part of large urban projects that comprise one of the cornerstones of NoHo Partners’ profitable growth strategy, which aims EUR 400 million...

Deposits grew by 52% year on year Bigbank’s total deposit portfolio as at the end of 2022 amounted to 1,367.8 million euros, 52% up on a year earlier. At the end of 2021, deposits totalled 898.3 million euros. Savings deposits, which accounted for 621.8 million euros of total deposits at the year-end, grew by 82% compared with a year earlier (341.2 million euros at the end of 2021). Term deposits, which amounted to 746 million euros at the end of 2022, grew by 34% year on year (557.1 million euros at the end of 2021). Loan portfolio grew by 50% year on year The gross portfolio of loans issued by Bigbank stood at 1,356.8 million euros at the end of 2022, reflecting 50% growth on a year earlier (903.9 million euros at the end of 2021). Loans to individuals and corporate customers accounted for 66% and 34% of the total loan portfolio, respectively....

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of $13.00 per share. The gross proceeds to Fulcrum from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $125 million. All shares in the offering are to be sold by Fulcrum Therapeutics. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to an additional 1,442,307 shares of its common stock. The offering is expected to close on or about January 20, 2023, subject to customary closing...

SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (“NDA”) for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Products Administration (the “NMPA”) for the treatment of the coronavirus disease 2019 (“COVID-19”). About Junshi BiosciencesFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company...

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“Neotorch”, NCT04158440) of the company’s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-containing doublet chemotherapy as perioperative treatment for operable non-small cell lung cancer (“NSCLC”) patients, has finished the pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of event-free survival (“EFS”) has met the pre-defined efficacy boundary. Junshi Biosciences...

GREELEY, Colo., Jan. 17, 2023 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its fourth quarter and fiscal year 2022 financial results after the U.S. market closes on Wednesday, February 8, 2023. The Company’s executives will review the results on a conference call and webcast on Thursday, February 9, 2023 at 7:00 a.m. MT (9:00 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with Pilgrim’s executive management team. Investors and analysts may pre-register for the webcast to receive a unique PIN to gain immediate access to the call and bypass the live operator. Pre-registration may be completed at any time, including up to and after the call has begun, by accessing the company’s investor website...

MONTRÉAL, Jan. 17, 2023 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$750 million aggregate principal amount of new Senior Notes due February 1, 2029. The new Senior Notes will carry a coupon of 7.50% per annum and will be sold at par (the “New Notes”). The issuance of the New Notes is expected to close on or about January 20, 2023, subject to customary closing conditions. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the redemption of all of its outstanding 7.500% Senior Notes due 2024 (the “2024 Notes”), of which there is $396 million aggregate principal amount outstanding on the date hereof, (ii) to finance the offer to purchase (the “2025 Tender Offer”) up to $354 million aggregate principal...

MONTRÉAL, Jan. 17, 2023 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier” or the “Company”) today announced an amendment with respect to its cash tender offer previously announced on January 17, 2023 (the “Tender Offer”) to purchase for cash up to $104,000,000 aggregate principal amount (exclusive of accrued and unpaid interest, and as such aggregate principal amount may be increased or decreased by the Company, the “Aggregate Maximum Principal Amount”) of its outstanding 7.50% Senior Notes due 2025 (the “Notes”). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Offer to Purchase dated January 17, 2023 (as amended hereby, the “Offer to Purchase”) with respect to the Tender Offer. The Tender Offer and the Offer to Purchase are hereby amended as follows:The Aggregate Maximum Principal...